Dr Reddys Laboratories News

May 29--Teva Pharmaceutical Industries Ltd. has decided not to market Atorvastatin, the generic version of Pfizer Inc.

Dr. Reddy's Laboratories , India's second-largest pharmaceutical company, recently reported a fourth-quarter and full-year 2012 performance that beat expectations on revenues but missed estimates on earnings.

Dr. Reddy's Laboratories Limited - SWOT Analysis company profile is the essential source for top-level company data and information.

Reddy's Laboratories Limited - Strategy and SWOT Report, is a source of comprehensive company data and information.

Pharmaceutical companies continue to take advantage of the uncertainty surrounding the safety of Pradaxa , as nine companies have gained approval to create the generic version of the blood thinning drug Plavix .

NEW YORK, May 22, 2012 /PRNewswire/ -- Genpact Limited , a global leader in business process and technology management, today announced that it has signed an agreement with Dr.

Analyst Report ), recently announced that it has received final approval from the U.S. Food & Drug Administration to launch generic versions of Plavix , 75 mg and 300 mg.

Reddy's Laboratories Limited - SWOT Analysis - a new company profile report on companiesandmarkets.com Dr.

HYDERABAD, India -- -- Dr. Reddy's Laboratories announced today that it has launched over-the-counter Lansoprazole delayed-release capsules in the U.S. market on May 18, 2012, following Dr.

Reddy's Laboratories Limited - SWOT Analysis - a new company profile report on companiesandmarkets.com Dr.

Dr. Reddy's Laboratories announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg , a bioequivalent generic version of PLAVIX, in the U.S. market on May 18, 2012.

Dr. Reddy's Laboratories reported higher-than-expected 4QFY2012 top-line performance, while its bottom line came in below expectations.

HYDERABAD, India-- --May 11, 2012 - Dr. Reddy's Laboratories Ltd. today announced its audited consolidated financial results for the quarter and full year ended March 31, 2012 under International Financial Reporting Standards .

Dr. Reddy's Laboratories Ltd. Friday disappointed investors with a slim 2.7% rise in its fourth-quarter net profit, but this was due mainly to a one-time charge.

Jobs Commodities Automobiles Insurance Real Estate Travel & Tourism Health & Pharma Lifestyle Media Power Telecom Infotech Retail Infrastructure Editor's Picks New Delhi: Drug firm Dr Reddy's Laboratories today reported 2.46 per cent increase in consolidated net profit to Rs 342.70 crore for the fourth quarter ended March 31, 2012, over the same ... (more)

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.